ASX announcement here. Bioxyne Limited (ASX code: BXN or the Company) advises that subsequent to the execution of a non-binding Heads of Agreement (HOA) to sell its HI-164 oral Vaccine project together with all of its Intellectual properties (IP) to Mariposa Health Limited (MHL), Dr. Phillip Comans has stepped down as Chief executive Officer of the […]
/wp-content/uploads/2018/01/BSM_logo.png00keymaster/wp-content/uploads/2018/01/BSM_logo.pngkeymaster2013-12-02 17:50:582018-01-06 17:51:37Bioxyne Ltd CEO Steps Down
/wp-content/uploads/2018/01/BSM_logo.png00keymaster/wp-content/uploads/2018/01/BSM_logo.pngkeymaster2013-11-25 17:52:252018-01-06 17:52:49Avita Medical – Results of Annual General Meeting
..Two largest shareholders to vote against remuneration report 20 November 2013: Leading Australian life sciences investment group BioScience Managers today confirmed it will vote against the remuneration report of spray-on skin company Avita Medical Limited (ASX:AVH) at the company’s AGM on Friday 22 November. With the company’s largest shareholder Australian Ethical also set to vote against […]
/wp-content/uploads/2018/01/BSM_logo.png00keymaster/wp-content/uploads/2018/01/BSM_logo.pngkeymaster2013-11-20 17:53:122018-01-06 17:53:40Avita Medical Facing First Strike
Biota Initiates Additional Clinical Trials of Laninamivir Octanoate Link here. ATLANTA, Nov. 19, 2013 (GLOBE NEWSWIRE) — Biota Pharmaceuticals Inc. (“Biota”) (Nasdaq:BOTA) announced today that it has commenced dosing in two Phase 1 clinical trials of laninamivir octanoate (“LANI”), its long-acting neuraminidase inhibitor being developed for the treatment of influenza. One of the Phase 1 clinical trials is a […]
/wp-content/uploads/2018/01/BSM_logo.png00keymaster/wp-content/uploads/2018/01/BSM_logo.pngkeymaster2013-10-22 17:53:512018-01-06 17:54:07Avita Medical Annual Report to shareholders
/wp-content/uploads/2018/01/BSM_logo.png00keymaster/wp-content/uploads/2018/01/BSM_logo.pngkeymaster2013-10-22 17:40:552018-01-06 17:41:49Notice of Annual General Meeting and explanatory memorandum to shareholders
Pharmaxis announcement link here. Pharmaceutical company Pharmaxis today announced the retirement of two non‐executive directors, Dr John Villiger and Mr Richard van den Broek. Dr Villiger joined the Board in November 2006. His career in the global pharmaceutical industry as a founder of The Medicines Company Inc. brought considerable clinical, regulatory and entrepreneurial experience to the […]
Auckland, New Zealand, September 6th 2013 – Nexus6 Ltd, a digital health company dedicated to improving respiratory care, today announced three appointments to its senior management team following the Company’s successful US$3.6m financing earlier in 2013. Nexus6 is a global leader in the development and manufacturing of intelligent monitoring solutions that improve the management of COPD and […]
/wp-content/uploads/2018/01/BSM_logo.png00keymaster/wp-content/uploads/2018/01/BSM_logo.pngkeymaster2013-09-06 17:42:062018-01-06 17:42:29Nexus6 Steps Up its Global Presence with Three New Appointments
Bioxyne Ltd CEO Steps Down
/in Portfolio CompaniesASX announcement here. Bioxyne Limited (ASX code: BXN or the Company) advises that subsequent to the execution of a non-binding Heads of Agreement (HOA) to sell its HI-164 oral Vaccine project together with all of its Intellectual properties (IP) to Mariposa Health Limited (MHL), Dr. Phillip Comans has stepped down as Chief executive Officer of the […]
Bioxyne Ltd – Sale of HI-164OV Hunter Immunology Pty Ltd
/in Portfolio CompaniesPlease find the ASX announcement here. Bioxyne divests its COPD related HI-164OV research program for up to $1.56 million.
Avita Medical – Results of Annual General Meeting
/in Avita Medical, Portfolio CompaniesLink here.
Avita Medical Facing First Strike
/in Avita Medical, Portfolio Companies..Two largest shareholders to vote against remuneration report 20 November 2013: Leading Australian life sciences investment group BioScience Managers today confirmed it will vote against the remuneration report of spray-on skin company Avita Medical Limited (ASX:AVH) at the company’s AGM on Friday 22 November. With the company’s largest shareholder Australian Ethical also set to vote against […]
Biota Initiates Additional Clinical Trials of Laninamivir Octanoate
/in Portfolio CompaniesBiota Initiates Additional Clinical Trials of Laninamivir Octanoate Link here. ATLANTA, Nov. 19, 2013 (GLOBE NEWSWIRE) — Biota Pharmaceuticals Inc. (“Biota”) (Nasdaq:BOTA) announced today that it has commenced dosing in two Phase 1 clinical trials of laninamivir octanoate (“LANI”), its long-acting neuraminidase inhibitor being developed for the treatment of influenza. One of the Phase 1 clinical trials is a […]
Avita Medical Annual Report to shareholders
/in Avita Medical, Portfolio CompaniesFinancial report 2013 link here.
Notice of Annual General Meeting and explanatory memorandum to shareholders
/in Avita Medical, Portfolio CompaniesLink here. Date of Meeting: 22 November 2013 Time of Meeting: 2pm WST Place of meeting: Function Room, QV1, 250 St Georges Terrace, Perth, WA 6000
Alchemia Ltd Investor Presentation September 2013
/in Portfolio CompaniesLink to the investor presentation here.
19.09.2013 – Pharmaxis Announces Two Board Retirements
/in Destiny Pharma, Portfolio CompaniesPharmaxis announcement link here. Pharmaceutical company Pharmaxis today announced the retirement of two non‐executive directors, Dr John Villiger and Mr Richard van den Broek. Dr Villiger joined the Board in November 2006. His career in the global pharmaceutical industry as a founder of The Medicines Company Inc. brought considerable clinical, regulatory and entrepreneurial experience to the […]
Nexus6 Steps Up its Global Presence with Three New Appointments
/in Adherium, Portfolio CompaniesAuckland, New Zealand, September 6th 2013 – Nexus6 Ltd, a digital health company dedicated to improving respiratory care, today announced three appointments to its senior management team following the Company’s successful US$3.6m financing earlier in 2013. Nexus6 is a global leader in the development and manufacturing of intelligent monitoring solutions that improve the management of COPD and […]